Presentations & Publications
Access a wide range of resources that provide detailed information on our products, programs, and collaborations.
Discovery Technology – Posters
2020
- 2020 EORTC-NCI-AACR: The non-peptidomimetic cIAP1/2 and XIAP antagonist tolinapant promotes an anti-tumour immune response in T-cell lymphoma
- Identification of potent small molecule allosteric inhibitors of SHP2
- Combined inhibition of SHP2 and ERK enhances anti-tumor effects in preclinical models
- The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 Inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models
- 2020 AACR: Fragment-based drug discovery to identify small molecule allosteric inhibitors of SHP2
- 2020 AACR: ASTX660, a non-peptidomimetic antagonist of cIAP1/2 and XIAP, promotes an anti-tumor immune response in pre-clinical models of T-cell lymphoma
- 2020 AACR: Different pharmacodynamic profiles of ERK1/2 inhibition can elicit comparable anti-tumor activity
- 2020 EHA: Characterization of ASTX660, an antagonist of cIAP1/2 and XIAP, in mouse models of T cell lymphoma
- 2020 EHA: ASTX295, a novel small molecule MDM2 antagonist, demonstrates potent activity in AML in combination with decitabine
2012
- Nature: Serine is a natural ligand and allosteric activator of pyruvate kinase M2
- Pyruvate Kinase M2: linking glycolysis to amino acid biosynthesis
- AACR: Pharmacodynamic and anti-tumor activity of fragment-derived inhibitors of MetAP2
- 2012 TAT: Anti-Angiogenic Activity of Fragment-Derived Inhibitors of METAP2
Product Archive
© Astex Pharmaceuticals
All rights reserved
